Next-Generation Checkpoint Combinations: Optimizing PD-(L)1-Based Therapy Across the Advanced, Adjuvant, and...

Area of Science:

• Oncology
• Immunotherapy
• Drug Development

Background:

• Programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors are key cancer therapies.
• Resistance to these inhibitors limits durable patient benefit.
• Focusing on renal cell carcinoma (RCC), urothelial cancer, and non-small cell lung cancer (NSCLC) provides mature, practice-relevant evidence.

Purpose of the Study:

• To review the development and positioning of PD-(L)1 inhibitor combinations in advanced, adjuvant, and neoadjuvant/perioperative settings.
• To examine cross-cutting strategies like dual checkpoint blockade, antibody-drug conjugates, and hypoxia-inducible factor (HIF)-2α inhibition.
• To contextualize these strategies within specific tumor types (RCC, urothelial cancer, NSCLC).

Main Methods:

• Review of mature, practice-relevant evidence for PD-(L)1-based combinations.
• Focus on three rapidly evolving tumor types: RCC, urothelial cancer, and NSCLC.
• Analysis of combination strategies across different disease stages (advanced, adjuvant, neoadjuvant/perioperative).

Main Results:

• In RCC, ICI plus VEGFR TKI doublets are standard; adjuvant pembrolizumab improves survival; HIF-2α inhibitor belzutifan is a post-ICI/TKI option.
• In bladder cancer, enfortumab vedotin plus pembrolizumab is first-line for advanced disease; perioperative durvalumab improves survival in muscle-invasive disease.
• In NSCLC, neoadjuvant/perioperative chemoimmunotherapy improves survival; failures include EGFR/ALK TKI combinations and anti-TIGIT antibodies.

Conclusions:

• Next-generation PD-(L)1 combinations are reshaping treatment for RCC, urothelial cancer, and NSCLC at all disease stages.
• Benefit magnitude, biomarkers, and toxicity differ significantly by tumor type and setting.
• Successful development requires strong biologic rationale, biomarker selection, and toxicity management.